TMS for Alzheimer's and Dementia

What is Alzheimer’s Disease and How TMS Helps

Alzheimer’s disease (AD) accounts for 60-80% of all dementia cases. It’s a progressive neurodegenerative disorder — amyloid-beta plaques and tau tangles build up in the brain, killing neurons and eroding memory, thinking, and the ability to get through a normal day. It usually starts in the hippocampus and entorhinal cortex (the brain’s memory-forming structures) before spreading to the parietal lobes, prefrontal cortex, and eventually the entire cerebral cortex.

But the damage goes deeper than lost neurons. Synaptic plasticity — the brain’s ability to strengthen and weaken connections — breaks down. Cortical excitability shifts. Neural networks lose their ability to talk to each other. The compensatory mechanisms that normally help your brain adapt to damage start failing. And these changes show up years before anyone notices symptoms.

Here’s what TMS can and can’t do: it cannot reverse neurodegeneration. That needs to be said plainly. What research suggests is that TMS may temporarily boost the function of neural circuits that are still intact. Targeted magnetic pulses can wake up underperforming networks, strengthen synaptic connections that have weakened but haven’t died yet, and engage the brain’s plasticity mechanisms. The earlier you start — when more functional brain tissue remains — the more room there is for benefit.

How TMS Works for Alzheimer’s Disease

TMS for Alzheimer’s targets different brain regions depending on which cognitive functions need support. The field has gotten more sophisticated over the past decade.

Left dorsolateral prefrontal cortex (DLPFC) stimulation at high frequency (10-20 Hz) targets executive function, attention, and working memory. The DLPFC takes a hit in moderate-stage AD, and boosting its activity can improve the top-down cognitive control that helps you manage daily tasks.

Parietal cortex stimulation goes after the default mode network and episodic memory retrieval. The precuneus and lateral parietal areas show early metabolic decline in AD — they’re critical nodes in the memory network.

Multi-site protocols are the most advanced approach. Pioneered by Neuronix (the neuroAD system) and refined by other groups, these protocols stimulate 6 different brain regions across treatment sessions — Broca’s area, Wernicke’s area, right and left DLPFC, and right and left parietal somatosensory association cortices. Here’s what makes it interesting: each region gets paired with a cognitive training exercise that engages that specific area during stimulation. The idea is that stimulating a brain region while simultaneously making it work produces stronger, longer-lasting neuroplastic changes than either intervention alone.

Typical parameters: high-frequency stimulation (10-20 Hz) at 90-120% of motor threshold, 1,500-2,000 pulses per session. Treatment courses run 20 to 30 sessions over 4-6 weeks, often followed by periodic maintenance.

Clinical Evidence and Success Rates

The evidence base has grown substantially. Large definitive trials are still ongoing, but here’s what we know so far.

A 2023 meta-analysis pooling data from 16 randomized controlled trials found that repetitive TMS produced modest but statistically significant improvements on the ADAS-Cog and MMSE cognitive scales. Improvements were larger in mild-to-moderate AD (compared to severe disease) and in studies using 20+ sessions combined with cognitive training.

What the research consistently shows:

• Cognitive improvements of 2-4 points on the ADAS-Cog scale — clinically meaningful, and comparable to what cholinesterase inhibitors like donepezil achieve
• About 40-50% of study participants show improvements in daily functioning and caregiver-rated outcomes
• Effects last 1-3 months after treatment ends; maintenance sessions every 1-2 months may extend benefits for 6-12 months
• Combined TMS plus cognitive training outperforms TMS alone or cognitive training alone. Every time.
• Patients with mild cognitive impairment (MCI) and early-stage AD respond better than those with moderate-to-severe disease
• A 2022 multicenter trial of the neuroAD system across 5 US and Israeli sites showed significant cognitive benefits in mild-moderate AD over 6 weeks, with some patients maintaining improvement at 12-week follow-up

The neuroAD device has CE marking in Europe for mild-to-moderate Alzheimer’s. In the United States, TMS remains not FDA-approved for any dementia indication. The FDA has reviewed submissions but wants more data from larger trials.

Who Qualifies for TMS Treatment

TMS for Alzheimer’s works best for a specific subset of patients. The ideal candidate looks like this:

• Mild cognitive impairment (MCI) or mild-to-moderate AD (MMSE scores roughly 15-26). You need enough remaining neural substrate for neuromodulation to work with.
• Already on standard AD medications (donepezil, rivastigmine, galantamine, memantine) with incomplete response. TMS is studied as an add-on, not a replacement for medication.
• Able to cooperate with repeated treatment sessions over 4-6 weeks. This means sufficient cognitive function, physical mobility, and caregiver support for daily clinic visits.
• No contraindications — no metallic implants near the head, no cardiac pacemakers (unless MRI-conditional), no active seizure disorder or seizure history.

Who is less likely to benefit:

• Those with severe dementia (MMSE below 10-12) — the neural substrate is too degraded for meaningful stimulation
• Patients with non-Alzheimer’s dementias (vascular, Lewy body, frontotemporal) — the evidence base is primarily for AD, and different dementias involve different brain circuits
• Anyone with significant behavioral or psychiatric symptoms preventing cooperation with sessions
• Patients with implanted metallic devices or fragments near the head

A thorough neurological evaluation — cognitive testing plus brain imaging — should happen before pursuing TMS. You need a confirmed diagnosis and a baseline to measure against.

What to Expect During Treatment

A standard course runs daily, 5 days per week, for 4-6 weeks (20-30 total sessions). Some protocols taper to 2-3 sessions per week, then shift to monthly or bimonthly maintenance.

Each session lasts about 40-60 minutes with cognitive training, or 20-30 minutes for TMS alone. The session starts with positioning the treatment coil over the target region. In multi-site protocols, the coil gets repositioned several times to hit different regions, with cognitive exercises woven between or during stimulation blocks.

You sit in a comfortable chair and stay fully awake throughout. The stimulation produces rhythmic clicking sounds and tapping sensations on the scalp. Most people find it tolerable. Some report mild discomfort that fades over the first few sessions.

When to expect changes:

• Subtle cognitive improvements may appear after 2-3 weeks
• Maximum benefit usually comes at the end of the course or shortly after
• Caregivers sometimes notice improvements in daily functioning, engagement, and communication before formal testing picks anything up
• Without maintenance sessions, benefits plateau and gradually fade over 1-3 months
• With regular maintenance, some patients sustain improvements for 6-12 months or longer

A word on expectations: TMS does not reverse Alzheimer’s or stop its progression. The goal is to help the brain work better with what it has left — and potentially slow the rate of decline. That’s worth pursuing, but it’s not a cure.

Side Effects and Safety

TMS has an excellent safety profile in Alzheimer’s patients. Side effects are mild and transient:

• Scalp discomfort at the stimulation site during treatment (20-30% of patients), usually less noticeable over time
• Mild headache after treatment (10-15%), usually handled by acetaminophen
• Fatigue after sessions — may be more noticeable in AD patients than younger populations
• Lightheadedness that resolves within minutes

Seizure risk is the most serious concern — estimated at less than 0.1% with standard safety protocols. That’s comparable to the general TMS population.

Here’s where TMS really stands out for older adults: no gastrointestinal side effects (common with cholinesterase inhibitors), no drug interactions (a big deal when you’re taking multiple medications), no sedation, and no burden on the liver or kidneys. For people who can’t tolerate AD medications, TMS offers a genuinely different path — though most clinicians use the two together.

Cognitive testing before and during treatment is recommended to track response and catch any unexpected effects.

TMS Devices Used for Alzheimer’s Disease

Several TMS platforms are used in Alzheimer’s research and clinical practice:

• Neuronix neuroAD System — Built specifically for Alzheimer’s. Combines TMS with synchronized cognitive training. The only system with CE marking for AD in Europe. Targets 6 brain regions with integrated cognitive exercises.
• Nexstim NBS System — MRI-guided neuronavigation for precise targeting of individual cortical regions. Used in research requiring customized targeting based on each patient’s brain anatomy.
• BrainsWay Deep TMS — H-coil technology that reaches broader and deeper cortical areas. Under study for AD applications where deeper stimulation may engage more of the affected memory networks.
• MagVenture MagPro — Versatile research-grade system used in numerous AD clinical trials. Supports various coil types and stimulation parameters.
• NeuroStar (Neuronetics) — The most widely available system. Primarily used when AD patients also have depression, using standard DLPFC protocols.

The neuroAD system is purpose-built for Alzheimer’s and offers the most complete protocol, but access is limited outside clinical trials. Standard TMS systems can deliver similar stimulation parameters — they just lack the built-in cognitive training component.

Cost and Insurance Coverage

TMS for Alzheimer’s is not covered by insurance in the United States. No FDA approval means no coverage. A complete treatment course typically runs $8,000 to $15,000 out of pocket, depending on session count, protocol, and clinic costs. Maintenance sessions add $200-500 each.

Ways to manage the cost:

• Clinical trials are the most affordable option — free treatment at leading academic institutions with access to cutting-edge protocols. Search ClinicalTrials.gov for “TMS Alzheimer” to find active studies.
• Comorbid depression opens a door. Depression affects 30-40% of AD patients. If your family member qualifies, TMS may be covered by insurance under the depression diagnosis — with cognitive benefits as a secondary gain.
• Academic medical centers sometimes offer reduced rates for patients willing to participate in outcome tracking and data collection.
• Payment plans at many clinics spread the cost over several months.
• Long-term care insurance policies occasionally cover experimental treatments — worth checking your policy.

There’s also an economic argument worth making: if TMS delays functional decline even modestly, the savings from reduced caregiver burden and delayed institutional placement can offset treatment costs. That math matters when memory care facilities cost $5,000-8,000 per month.

Finding a TMS Provider

This is a specialized application. You need more than a clinic that treats depression with TMS.

What to look for:

• Experience with neurological patients and cognitive disorders, not just psychiatric conditions
• Familiarity with multi-site stimulation protocols and cognitive training integration
• Access to neuronavigation for precise brain targeting
• A working relationship with neurologists and geriatric specialists
• Ability to do baseline and follow-up cognitive assessments to actually measure whether treatment is working

Questions to ask:

• What protocol do you use for Alzheimer’s patients, and how many AD patients have you treated?
• Do you combine TMS with cognitive training exercises during sessions?
• How do you target specific brain regions — neuronavigation or anatomical landmarks?
• What outcomes have you seen in your AD patients?
• Do you offer maintenance sessions, and what does your long-term plan look like?

Where to find treatment:

• Clinical trials at academic memory disorder centers — best option for cutting-edge protocols with expert oversight
• University-affiliated neurology departments conducting neuromodulation research
• ClinicalTrials.gov — search “transcranial magnetic stimulation Alzheimer” for recruiting studies
• Alzheimer’s Association (alz.org) — can refer you to research centers in your area
• Be wary of clinics aggressively marketing TMS as an Alzheimer’s treatment. The evidence supports potential benefit, not proven efficacy. Anyone promising a cure is selling something.

Frequently Asked Questions

Can TMS cure Alzheimer’s disease or stop it from progressing? No. TMS cannot cure Alzheimer’s or halt the underlying neurodegeneration. It may temporarily sharpen cognitive function by helping remaining neural circuits work more efficiently and promoting compensatory plasticity. Think of it as helping the brain do more with what it has left — not reversing the disease itself.

How is TMS different from the medications approved for Alzheimer’s? AD medications (donepezil, rivastigmine, memantine) work by changing neurotransmitter levels throughout the brain. TMS directly stimulates specific brain regions involved in memory and cognition — a completely different mechanism. The two can work together, and combined treatment may produce better results than either alone.

Is TMS appropriate for my family member with moderate-to-severe Alzheimer’s? Honestly, the research consistently shows TMS is most effective in mild cognitive impairment or mild-to-moderate AD. In severe disease, too much neural tissue is gone for neuromodulation to make a meaningful difference. If your family member has an MMSE score below 10-12, TMS is unlikely to help significantly.

How long do cognitive improvements last after TMS treatment? Without maintenance, improvements typically last 1-3 months before gradually fading. With regular maintenance sessions (monthly or bimonthly), some patients hold onto benefits for 6-12 months or longer. Long-term outcomes beyond one year aren’t well established yet.

Does TMS for Alzheimer’s have the same side effects as TMS for depression? Yes — same profile. Mild scalp discomfort, occasional headache, very rare seizure risk. Elderly AD patients may be a bit more tired after sessions. But serious adverse effects are uncommon, and TMS is notably easier to tolerate than the GI side effects that come with cholinesterase inhibitors.